FDA Peptide Review
FDA Considering Reclassifying 14 Restricted Peptides
- During its high-stakes meeting on July 23–24, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) narrowly voted to recommend adding six of the seven reviewed peptides to the Section 503A Bulk Drug Substances List.
- This narrow vote directly opposed the recommendation of the FDA’s own staff scientists, who advised against inclusion for all seven, citing a lack of robust human safety and clinical data.
- The panel’s task was to determine whether licensed compounding pharmacies should be permitted to custom-manufacture specific unapproved peptides.
July 2026 PCAC Peptide Recommendations
| Recommendation Status | Peptide Name | Common Uses / Proposed Indications |
| Recommended for 503A List (Voted to Allow Compounding) |
BPC-157 | Tissue healing, gut health, joint repair |
| TB-500 (Thymosin Beta-4) | Wound healing, muscle recovery, inflammation | |
| KPV | Anti-inflammatory, antimicrobial, gut health | |
| MOTS-c | Mitochondrial function, metabolic health, energy | |
| Semax | Cognitive enhancement, neuroprotection, focus | |
| Epitalon | Anti-aging, longevity, sleep regulation | |
| Ruled Against (Rejected for Compounding) |
Emideltide (DSIP) | Chronic pain, sleep disorders, opioid withdrawal |
Supporters, including HHS Secretary Robert F. Kennedy Jr., pushed for the expansion as a way to transition users away from an unregulated, gray-market online landscape of unverified “research grade” imports.
What Does This Mean, Exactly?
- The PCAC’s vote is non-binding and advisory only. It remains currently illegal for U.S. pharmacies to compound these six substances until the FDA completes formal rule-making. We see this as a positive step — not a determinate legal outcome, but a sign the current administration is willing to directly confront the black- and gray-market landscape.
- Complete addition to the 503A Bulks List requires formal administrative rule-making and final sign-off from the HHS Secretary, which typically takes significant time. A second PCAC meeting has already been scheduled to review the remaining peptides on Secretary Kennedy’s original list of 14.
Our Opinion
It’s fair to look at these proceedings and wonder why a regulatory agency is dedicating so much attention to this specific issue. To understand the FDA’s hesitation, it helps to look at how approval normally works: historically, the FDA reviews clinical trial data that’s already been extensively cleaned, analyzed, and packaged by a sponsoring pharmaceutical company. The agency rarely digs into raw data or runs studies in-house.
Because traditional pharmaceutical companies aren’t funding large-scale trials for these specific peptides, existing datasets remain small and occasionally lack rigorous methodology. This puts the FDA in an unusual position — without a major pharmaceutical sponsor to defer to, agency officials must take direct responsibility for the decision to permit or restrict compounding.
There’s clearly significant public interest in these therapies. But the current landscape carries real risk when people seek access outside regulated medical channels, potentially encountering substances of unverified purity and origin. Patient interest is high, and it’s essential that any clinical use be supported by rigorous safety standards and formal oversight.
From a clinical standpoint, the priority is always expanding robust data collection — comprehensive evidence is necessary to establish standardized treatment protocols and protect long-term patient safety. Integrating these therapies into mainstream medicine is a worthwhile goal, but a thorough, evidence-based approach has to come first.
Original publication date: 4/14/2026
The FDA is formally reviewing whether to reclassify up to 14 peptides restricted under Category 2 in late 2023. The review involves a series of public PCAC meetings — the first held in July 2026, with a second scheduled for 2027 — to determine whether these substances should return to Category 1, allowing routine compounding by Section 503A pharmacies.
While an official final list is still pending, the following peptides have been named for review, per statements from HHS Secretary Robert F. Kennedy Jr.:
Peptides Reviewed in July 2026
- BPC-157: studied for tissue repair, gut healing (including ulcerative colitis), and inflammation reduction.
- TB-500 (Thymosin Beta-4 fragment): studied for muscle repair, wound healing, and recovery.
- KPV: an anti-inflammatory peptide studied for wound healing and gut health.
- MOTS-c: a mitochondrial peptide studied for metabolic regulation, obesity, and osteoporosis.
- Emideltide (DSIP): studied for opioid withdrawal, chronic insomnia, and narcolepsy. (Not recommended by the PCAC.)
- Semax: a neuropeptide studied for cognitive function, migraine relief, and circulatory issues.
- Epitalon: studied for its effects on sleep and aging-related processes.
Peptides Slated for 2027 Review
- Thymosin Alpha-1 (Tα1): studied for immune system modulation.
- GHK-Cu (Copper Peptide): studied for skin health and wound healing.
- CJC-1295: a growth hormone-releasing peptide studied for metabolism and muscle support.
- Ipamorelin: often studied alongside CJC-1295 for natural growth hormone stimulation.
- Selank: a neuropeptide studied for anxiety management and neuroprotection.
- Cathelicidin (LL-37): studied for antimicrobial and wound-healing properties.
- Dihexa Acetate: studied for cognitive health and neuroprotection.
- AOD-9604: a fragment of human growth hormone studied for fat metabolism.
What This Means for Patients Currently Using Compounded Peptides
To be clear, most of these peptides are currently available only through sterile compounding pharmacies holding special licenses for sterile — and in some cases biologic — compounding. A recent USP General Chapter <797> update outlined requirements for injectable compounds, including beyond-use dates, storage requirements, and compounding specifications.
All pharmacies that manufacture any compound must source their active pharmaceutical ingredient (API) from a verified USP provider or importer to ensure safety and sterility.
Our compounding partner facility.
Below are some of the compliance standards API sourcing companies must meet to supply U.S. compounding pharmacies:
- FDA Registration: the manufacturer must be registered with the FDA under Section 510.
- Monograph Compliance: where a USP/NF monograph exists for a substance, the bulk material must strictly comply with those standards.
- Exclusion of “Research Use Only” (RUO) Material: pharmacies are prohibited from sourcing peptides labeled for research use only, since these don’t meet the clinical-grade standards required for human — especially sterile injectable — administration.
The compounding pharmacies we work with perform extensive third-party testing on each manufactured batch: raw material is tested before compounding, and the formulated product is tested again before reaching patients. Each batch of sterile injectable medication must meet baseline safety standards, typically verified through:
- Sterility Testing: the primary defense against microbial contamination, incubating samples to detect bacteria or fungi. 503B facilities must test every batch before release; beyond-use dates are also tested for storage, temperature, and shelf life.
- Endotoxin Testing: targets pyrogens — microbial byproducts that can cause severe fever or shock if injected. Mandatory for all 503B products and for 503A high-risk compounds made from non-sterile starting ingredients.
- Potency Testing: confirms the active ingredient’s concentration matches the label exactly. Required for every 503B batch; most 503A pharmacies also perform this voluntarily for dosing consistency.
- Particulate Matter Inspection: a visual or automated check confirming the liquid is clear and free of visible fibers, glass shards, or undissolved precipitates.
These rules apply only to peptides and compounds produced by U.S.-based, licensed compounding pharmacies — not to “research use only” or black-market products, which are sold and labeled “Not for Human Use” as a loophole rather than a genuine research safeguard. At MedClub, we support the FDA’s current review process. There’s significant demand for these compounds paired with limited patient education, and high demand with short legal supply tends to fuel a robust black market — most people don’t realize they’re risking exposure to dangerous bacteria and endotoxins when injecting a product purchased online under a “Research Use Only” label. We’ve seen peptides support meaningful patient outcomes across a range of concerns, and we want to keep offering that while giving patients confidence that what we source and use meets the highest available safety standards.
Check out our YouTube channel for updates
MedClub by Dr. Jenn — Subscribe for the latest peptide news →
We’ll update this article as new information becomes available. Stay tuned.
This article reflects the status of FDA regulatory proceedings as of the dates noted above — this is an evolving situation and details may change. The “Our Opinion” section reflects MedClub’s own editorial perspective, not a statement of fact or FDA policy. None of the peptides discussed here are FDA-approved, and none may currently be legally compounded by U.S. pharmacies unless and until the FDA completes formal rule-making.